Skip to main content
. 2020 Dec 18;6(51):eabd7272. doi: 10.1126/sciadv.abd7272

Fig. 2. β cell loss requires Ripk3.

Fig. 2

(A) β cell–protective effect of a RIPK1 inhibitor (Nec-1) and a RIPK3 inhibitor (GSK’872). Data represent means ± SEM (n > 15 per group). *P < 0.05; one-way ANOVA, Tukey’s multiple comparisons test. DMSO, dimethyl sulfoxide. (B) Requirement of ripk3 for the β cell loss. Data represent means ± SEM (n > 10 per group). *P < 0.05; one-way ANOVA, Tukey’s multiple comparisons test. (C) Maintenance of whole-body glucose content in ripk3−/−, zMIR larvae after three sessions of overnutrition. Data represent means ± SEM (n = 4 per group). *P < 0.05; one-way ANOVA, Tukey’s multiple comparisons test. (D) Punctate distribution of mutant RIPK3 in zMIR but not in non-zMIR β cells at hour 64. Scale bars, 5 μm. (E) Protective effect of β cell–specific inhibition of RIPK3 on β cells. Data represent means ± SEM (n > 25 per group). *P < 0.05; one-way ANOVA, Tukey’s multiple comparisons test. (F) Effect of β cell–specific inhibition of RIPK3 on whole-body free glucose content. Data represent means ± SEM (n = 4 per group). *P < 0.05; one-way ANOVA, Tukey’s multiple comparisons test. (G) GSK’872 prevents palmitate-impaired insulin secretion. Average insulin secretion per islet at 1 mM and 16.7 mM glucose from mouse islets treated with or without 0.5 mM palmitate in the presence or absence of 3 μM GSK’872. Data represent means ± SEM (n = 3 per group). **P ≤ 0.01 and ***P ≤ 0.001; two-way ANOVA, Tukey’s multiple comparisons test.